| Home | Log In | Register | Our Services | My Account | Contact | Help |
- 16 Jun 2013 21:12


- 04 Sep 2014 07:09
- 86 of 201
- 08 Sep 2014 17:28
- 88 of 201
- 11 Sep 2014 17:09
- 89 of 201
- 19 Sep 2014 07:13
- 90 of 201
- 27 Sep 2014 19:54
- 91 of 201
- 17 Oct 2014 16:13
- 92 of 201
- 20 Oct 2014 16:58
- 93 of 201
- 21 Oct 2014 19:52
- 94 of 201
- 24 Oct 2014 14:55
- 96 of 201
- 01 Nov 2014 22:11
- 97 of 201
- 07 Nov 2014 16:24
- 98 of 201
- 10 Nov 2014 16:19
- 99 of 201
- 11 Nov 2014 18:20
- 101 of 201
- 11 Nov 2014 19:01
- 102 of 201
Sphere Medical is a dynamic and growing company specialising in the development of innovative medical monitoring and diagnostic equipment. Their products are used in a wide range of medical applications, enabling faster clinical decision-making and improved patient outcomes, whilst providing efficiencies that result in reduced healthcare costs.VALIRX (AIM:VAL)
Valirx Plc is an oncology-focussed Biopharmaceutical Company, developing treatments and diagnostics. Technologies are selected by using rigorous clinical and commercial processes to address unmet market needs. Clinical lead product is VAL201, a peptide for prostate cancer with follow-on indications in ovarian and breast cancers and endometriosis. Product VAL401, is a small molecule reformulation for lung cancers. The Company’s proprietary technology platform, GeneICE, enables selective silencing of rebellious genes’ inappropriate activity. VAL101, the first GeneICE therapeutic, targets and reduces expression of Bcl-2, implicated in about half of cancers. GeneICE extension to neurology and inflammatory diseases will follow. A novel diagnostic, the Nav3 system, detects pre-cancerous, cancerous and metastatic cells in tissue samples even before a tumour forms; indicating potential malignant formation.
Speaker: Satu Vainikka, CEO


- 14 Nov 2014 11:05
- 103 of 201